Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF 77 5-Year Share Buyback Ratio is 0.10 as of Jun. 2026. GuruFocus rates MEDGF with a GF Score™ of 77/100 and a GF Value™ of $218.70 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 637 Medical Devices & Instruments companies, Medacta Group ranks better than 86.19% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Medacta Group's current 5-Year Share Buyback Ratio was 0.10%.
MEDGF's 5-Year Share Buyback Ratio is ranked better than 86.19% of 637
companies
in the Medical Devices & Instruments industry
Industry Median: -3.4
vs MEDGF: 0.10
Medacta Group (OTCPK:MEDGF) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Medacta Group 5-Year Share Buyback Ratio Related Terms
MEDGF vs ABT, SYK, MDT: 5-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Medacta Group's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group 5-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Medacta Group's 5-Year Share Buyback Ratio falls into.
Medacta Group 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of 0.10 mean?
Medacta Group (MEDGF) has a 5-Year Share Buyback Ratio of 0.10 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #88 out of 637 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Medacta Group's 5-Year Share Buyback Ratio too high?
Medacta Group's current 5-Year Share Buyback Ratio is 0.10. Based on the distribution chart, Medacta Group ranks #88 out of 637 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medacta Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's 5-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #88 out of 637 companies for 5-Year Share Buyback Ratio. This places Medacta Group in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 5-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Medacta Group and its competitors. Medacta Group's current 5-Year Share Buyback Ratio is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $218.70, compared to a current price of $150.06 — trading 31.4% below its estimated fair value. The current 5-Year Share Buyback Ratio is 0.10. Medacta Group's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Medacta Group (MEDGF), the current 5-Year Share Buyback Ratio is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of $150.06 is trading 31.4% below its estimated GF Value™ of $218.70.
GuruFocus considers Medacta Group to be Significantly Undervalued.
Key valuation signals for MEDGF:
5-Year Share Buyback Ratio: 0.10
GF Value™: $218.70 vs. price of $150.06 (31.4% below fair value)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
77GF Score
Get the complete analysis for MEDGF
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
